15.95
-0.17 (-1.05%)
| 前收盘价格 | 16.12 |
| 收盘价格 | 16.35 |
| 成交量 | 96,578 |
| 平均成交量 (3个月) | 22,062 |
| 市值 | 21,121,760 |
| 价格/销量 (P/S) | 1.02 |
| 股市价格/股市净资产 (P/B) | 1.20 |
| 52周波幅 | |
| 利润日期 | 14 Nov 2024 - 18 Nov 2024 |
| 营业毛利率 | -114.11% |
| 营业利益率 (TTM) | -56.90% |
| 稀释每股收益 (EPS TTM) | -19.21 |
| 季度收入增长率 (YOY) | -97.30% |
| 流动比率 (MRQ) | 3.95 |
| 营业现金流 (OCF TTM) | -37.87 M |
| 杠杆自由现金流 (LFCF TTM) | -25.49 M |
| 资产报酬率 (ROA TTM) | -13.18% |
| 股东权益报酬率 (ROE TTM) | -80.46% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Pieris Pharmaceuticals, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 0.0 |
| 平均 | -0.75 |
|
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.07% |
| 机构持股比例 | 47.71% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合